CoChat

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Open access

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

Tolerance to self-antigens prevents the elimination of cancer by the immune system 1,2. We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and mediate tumor rejection in patients with chronic lymphocytic leukemia (CLL). Remission was induced in a subset of subjects, but most did not respond. Comprehensive assessment of patient-derived CAR T cells to identify mechanisms of therapeutic success and failure has not been explored. We performed genomic, phenotypic and functional evaluations to identify determinants of response. Transcriptomic profiling revealed that CAR T cells from complete-responding patients with CLL were enriched in memory-related genes, including IL-6/STAT3 signatures, whereas T cells from nonresponders upregulated programs involved in effector differentiation, glycolysis, exhaustion and apoptosis. Sustained remission was associated with an elevated frequency of CD27+CD45RO-CD8+ T cells before CAR T cell generation, and these lymphocytes possessed memory-like characteristics. Highly functional CAR T cells from patients produced STAT3-related cytokines, and serum IL-6 correlated with CAR T cell expansion. IL-6/STAT3 blockade diminished CAR T cell proliferation. Furthermore, a mechanistically relevant population of CD27+PD-1-CD8+ CAR T cells expressing high levels of the IL-6 receptor predicts therapeutic response and is responsible for tumor control. These findings uncover new features of CAR T cell biology and underscore the potential of using pretreatment biomarkers of response to advance immunotherapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-018-0010-1

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 1,785

Metadata

Authors
Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., Pequignot, E., Ambrose, D. E., Zhang, C., Wilcox, N., Bedoya, F., Dorfmeier, C., Chen, F., Tian, L., Parakandi, H., Gupta, M., Young, R. M., Johnson, F. B., Kulikovskaya, I., Liu, L., Xu, J., Kassim, S. H., Davis, M. M., Levine, B. L., Frey, N. V., Siegel, D. L., Huang, A. C., Wherry, E. J., Bitter, H., Brogdon, J. L., Porter, D. L., June, C. H., & Melenhorst, J. J.
Affiliations
  • University of Pennsylvania (US)
  • Parker Institute for Cancer Immunotherapy (US)
Corresponding author
Melenhorst, J. Joseph
Venue
Nature Medicine
Published
2018-04-30
Volume
24
Issue
5
Pages
563-571
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2801641802
Cited by
1,785
References
57
Citations by year
2026: 218 · 2025: 223 · 2024: 248 · 2023: 231 · 2022: 248 · 2021: 229 · 2020: 206 · 2019: 138 · 2018: 41
FWCI
57.66
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (T32CA009140, R01CA165206, P01CA214278, P30CA016520)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
chronic lymphocytic leukemia, CAR T-cell therapy, CD19 chimeric antigen receptor, treatment response, resistance mechanisms, IL-6/STAT3 signaling, IL-6 receptor, tumor immune tolerance, gene expression profiling, predictive biomarkers, T cell exhaustion, CD8+ T cells
MeSH terms
Receptors, Chimeric Antigen, Animals, Female, Male, Transcription, Genetic, Leukemia, Lymphocytic, Chronic, B-Cell, Interleukin-6, Immunotherapy, Adoptive, Treatment Outcome, Antigens, CD19, STAT3 Transcription Factor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.